PDT Partners LLC Acquires 99,539 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

PDT Partners LLC increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 39.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 352,498 shares of the biopharmaceutical company’s stock after acquiring an additional 99,539 shares during the period. PDT Partners LLC’s holdings in Amicus Therapeutics were worth $3,321,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Amicus Therapeutics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 29,258,963 shares of the biopharmaceutical company’s stock valued at $275,619,000 after acquiring an additional 458,143 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Amicus Therapeutics by 18.8% in the fourth quarter. Wellington Management Group LLP now owns 28,461,994 shares of the biopharmaceutical company’s stock worth $268,112,000 after buying an additional 4,497,950 shares during the last quarter. Northern Trust Corp lifted its position in Amicus Therapeutics by 5.9% during the 4th quarter. Northern Trust Corp now owns 3,371,639 shares of the biopharmaceutical company’s stock worth $31,761,000 after acquiring an additional 187,652 shares during the period. Massachusetts Financial Services Co. MA raised its position in Amicus Therapeutics by 3.4% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 3,267,375 shares of the biopharmaceutical company’s stock worth $30,779,000 after buying an additional 107,348 shares during the last quarter. Finally, Norges Bank acquired a new stake in Amicus Therapeutics during the 4th quarter valued at approximately $29,033,000.

Amicus Therapeutics Trading Up 0.5 %

NASDAQ FOLD opened at $7.39 on Tuesday. The firm’s fifty day moving average is $8.11 and its two-hundred day moving average is $9.37. Amicus Therapeutics, Inc. has a one year low of $6.20 and a one year high of $12.65. The firm has a market cap of $2.27 billion, a PE ratio of -41.06, a P/E/G ratio of 1.51 and a beta of 0.79. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39.

Wall Street Analysts Forecast Growth

FOLD has been the topic of several recent research reports. Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating on the stock in a research report on Thursday, February 20th. Cantor Fitzgerald reissued an “overweight” rating and set a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Finally, Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.